Yes, 100 mg daily oral micronized progesterone provides adequate endometrial protection in women with an intact uterus receiving continuous estrogen therapy.
The American Association of Clinical Endocrinologists (AACE) guidelines explicitly state that micronized progesterone at 100 mg daily has been shown to provide endometrial protection (EL 1: RCT evidence) 1. This is also confirmed by FDA labeling, which approves 200 mg daily for 12 days sequentially but acknowledges the continuous daily dosing regimen 2.
Dosing Regimens for Endometrial Protection
The evidence supports two validated approaches with micronized progesterone:
- Continuous daily dosing: 100 mg daily provides endometrial protection when combined with continuous estrogen 1
- Sequential dosing: 200 mg daily for 10-14 days per month (or 12 days per 28-day cycle) 1, 2
For continuous combined therapy specifically, 100 mg daily is the established protective dose 1. This regimen has the advantage of inducing amenorrhea in most women (>90% by 6 months), which improves compliance compared to sequential regimens that cause monthly bleeding 3.
Evidence Quality and Strength
The AACE guidelines rate this recommendation as Grade A (EL 1: RCT), meaning it's based on high-quality randomized controlled trial evidence 1. Multiple studies confirm that 100 mg daily micronized progesterone:
- Fully inhibits endometrial mitoses 3, 4
- Prevents endometrial hyperplasia 3, 4
- Maintains quiescent or minimally active endometrium 3, 4
A systematic review confirms that oral micronized progesterone at 100 mg daily provides endometrial protection for continuous combined therapy, though the evidence is strongest for sequential use at 200 mg for 12-14 days 5.
Critical Caveats
Duration of safe use: The evidence for 100 mg daily continuous dosing is validated for up to 3-5 years 5. Beyond this timeframe, endometrial surveillance becomes more important.
Sequential regimens beyond 5 years: The Endocrine Society guidelines note that micronized progesterone in combination with estrogen has been associated with approximately 2-fold increased endometrial cancer risk when continued beyond 5 years in observational studies, though RCTs up to 3 years showed endometrial safety 6. This discrepancy may reflect compliance issues with sequential dosing.
Monitoring requirements: Any unexpected vaginal bleeding requires prompt endometrial evaluation with ultrasound and biopsy, regardless of the regimen used 1. The threshold for endometrial sampling should be low, as bleeding patterns don't reliably predict abnormal histology 1.
Advantages of 100 mg Daily Dosing
- High amenorrhea rates (91-93% by 6 months), improving compliance 3
- Potentially lower breast cancer risk compared to synthetic progestogens 7, 8, 9
- Does not attenuate cardiovascular benefits of estrogen 7
- Fewer progestogenic side effects (mood changes, bloating) compared to higher doses 1
Alternative if 100 mg Daily is Insufficient
If breakthrough bleeding occurs or endometrial surveillance shows inadequate protection, increase to 200 mg daily continuously or switch to sequential dosing at 200 mg for 12-14 days per month 1, 5. The FDA-approved sequential regimen (200 mg for 12 days per 28-day cycle) has the strongest regulatory backing 2.
Take progesterone at bedtime due to sedative effects and potential dizziness 2. If swallowing difficulties occur, take with water while standing 2.